Systemic lupus erythematosus: 2006 Update

Journal of Clinical Rheumatology

Volumn 12, Issue 1, 2006, Pages 37-40

  Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; AUTOANTIBODY; AZATHIOPRINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CD22 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; ECHINACEA EXTRACT; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MERCURY; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; RITUXIMAB; SILICON DIOXIDE; SULFONAMIDE; THALIDOMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN D;

ACNE; ARTHRITIS; ATHEROSCLEROSIS; AVASCULAR NECROSIS; B LYMPHOCYTE; CATARACT; CIGARETTE SMOKING; CLINICAL FEATURE; COGNITIVE DEFECT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; FATIGUE; GLAUCOMA; HEALTH STATUS; HIRSUTISM; HORMONE ACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; NEUROPATHY; NONHUMAN; OBESITY; OSTEOPOROSIS; OVARY INSUFFICIENCY; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; SKIN LUPUS ERYTHEMATOSUS; STROKE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOSIS; ULTRAVIOLET IRRADIATION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; ANIMAL; CHRONIC DISEASE; CLINICAL TRIAL; PATHOLOGY; QUALITY OF LIFE; RISK FACTOR;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE; RISK FACTORS;

EID: 33745911145     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000200420.67262.04     Document Type: Review

References (28)

1. Fessel WJ. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974;134:1027-1035.
2. McAlindon TE, Gulin J, Chen T, et al. Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus. 2001;10:779-783.
3. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46:1820-1829.
4. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 1995;38:1826-1831.
5. Casciola-Rosen L, Rosen A, Petri M, et al. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in SLE. Proc Natl Acad Sci U S A. 1996;96:1624-1629.
6. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100:2610-2615.
7. Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 2004;50:849-857.
8. Chiou SH, Lan JL, Lin SL, et al. Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus. 2004;13:442-449.
9. Zarmbinski MA, Messner RP, Mandel JS. Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus. J Rheumatol. 1992;19:1380-1384.
10. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100:3019-3026.
11. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44:1122-1126.
12. Cooper GS, Parks CG, Treadwell EL, et al. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol. 2004;31:1928-1933.
13. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-1533.
14. Nived O, Sturfelt G, Liang MH, et al. The ACR nomenclature for CNS lupus revisited. Lupus. 2003;12:872-876.
15. Edworthy SM, Zatarain E, McShane DJ, et al. Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology: new insights to the relative merit of individual criteria. J Rheumatol. 1988;15:1493-1498.
16. Barr S, Zonana-Nacach A, Magder L, et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999;42:2682-2688.
17. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. In press.
18. Ho A, Magder L, Barr S, et al. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2342-2349.
19. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408-415.
20. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513-519.
21. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
22. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-1808.
23. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-2406.
24. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150-154.
25. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
26. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156-1162.
27. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
28. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161-3169.